1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014

Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014" provides data on the Wegener’s Granulomatosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Wegener’s Granulomatosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Wegener’s Granulomatosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Wegener's Granulomatosis Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Wegener's Granulomatosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Wegener's Granulomatosis to Immunology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Wegener's Granulomatosis to Immunology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Wegener's Granulomatosis 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Wegener's Granulomatosis Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
F. Hoffmann-La Roche Ltd. 30
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 30
Nippon Kayaku Co., Ltd. 31
Clinical Trial Overview of Nippon Kayaku Co., Ltd. 31
Zenyaku Kogyo Co., Ltd. 32
Clinical Trial Overview of Zenyaku Kogyo Co., Ltd. 32
Nordic Pharma Group 33
Clinical Trial Overview of Nordic Pharma Group 33
Human Genome Sciences, Inc. (Inactive) 34
Clinical Trial Overview of Human Genome Sciences, Inc. (Inactive) 34
Anthera Pharmaceuticals‚ Inc. 35
Clinical Trial Overview of Anthera Pharmaceuticals‚ Inc. 35
Clinical Trial Overview of Top Institutes / Government 36
The National Institute of Allergy and Infectious Diseases 36
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 36
Assistance Publique - Hopitaux de Paris 37
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 37
University of Pennsylvania 38
Clinical Trial Overview of University of Pennsylvania 38
Cambridge University Hospitals NHS Foundation Trust 39
Clinical Trial Overview of Cambridge University Hospitals NHS Foundation Trust 39
University of Oxford 40
Clinical Trial Overview of University of Oxford 40
National Cancer Institute 41
Clinical Trial Overview of National Cancer Institute 41
University Medical Center Groningen 42
Clinical Trial Overview of University Medical Center Groningen 42
University Hospitals Birmingham NHS Foundation Trust 43
Clinical Trial Overview of University Hospitals Birmingham NHS Foundation Trust 43
Northwestern University 44
Clinical Trial Overview of Northwestern University 44
Children's Hospital of Eastern Ontario 45
Clinical Trial Overview of Children's Hospital of Eastern Ontario 45
Five Key Clinical Profiles 46
Appendix 76
Abbreviations 76
Definitions 76
Research Methodology 77
Secondary Research 77
About GlobalData 78
Contact Us 78
Disclaimer 78
Source 78

List of Tables

Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Wegener's Granulomatosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Wegener's Granulomatosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Wegener's Granulomatosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Wegener's Granulomatosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, G7 Countries (%), 2014* 14
Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, E7 Countries (%), 2014* 17
Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Wegener's Granulomatosis Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Wegener's Granulomatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 30
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nippon Kayaku Co., Ltd., 2014* 31
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zenyaku Kogyo Co., Ltd., 2014* 32
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nordic Pharma Group, 2014* 33
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Human Genome Sciences, Inc. (Inactive), 2014* 34
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Anthera Pharmaceuticals‚ Inc., 2014* 35
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 36
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 37
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 38
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cambridge University Hospitals NHS Foundation Trust, 2014* 39
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014* 40
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 41
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medical Center Groningen, 2014* 42
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals Birmingham NHS Foundation Trust, 2014* 43
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 44
Wegener's Granulomatosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital of Eastern Ontario, 2014* 45

List of Figures

Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Wegener's Granulomatosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Wegener's Granulomatosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Wegener's Granulomatosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Wegener's Granulomatosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 13
Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, G7 Countries (%), 2014* 14
Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Wegener's Granulomatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Wegener's Granulomatosis to Immunology Clinical Trials, E7 Countries (%), 2014* 17
Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Wegener's Granulomatosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Wegener's Granulomatosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Wegener's Granulomatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Wegener's Granulomatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 77

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.